612 related articles for article (PubMed ID: 36159846)
1. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
3. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.
Angyal A; Longet S; Moore SC; Payne RP; Harding A; Tipton T; Rongkard P; Ali M; Hering LM; Meardon N; Austin J; Brown R; Skelly D; Gillson N; Dobson SL; Cross A; Sandhar G; Kilby JA; Tyerman JK; Nicols AR; Spegarova JS; Mehta H; Hornsby H; Whitham R; Conlon CP; Jeffery K; Goulder P; Frater J; Dold C; Pace M; Ogbe A; Brown H; Ansari MA; Adland E; Brown A; Chand M; Shields A; Matthews PC; Hopkins S; Hall V; James W; Rowland-Jones SL; Klenerman P; Dunachie S; Richter A; Duncan CJA; Barnes E; Carroll M; Turtle L; de Silva TI;
Lancet Microbe; 2022 Jan; 3(1):e21-e31. PubMed ID: 34778853
[TBL] [Abstract][Full Text] [Related]
4. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
5. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
Gorochov G; Ropers J; Launay O; Dorgham K; da Mata-Jardin O; Lebbah S; Durier C; Bauer R; Radenne A; Desaint C; Vieillard LV; Rekacewicz C; Lachatre M; Parfait B; Batteux F; Hupé P; Ninove L; Lefebvre M; Conrad A; Dussol B; Maakaroun-Vermesse Z; Melica G; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Dualé C; Ansart S; Botelho-Nevers E; Lelièvre JD; de Lamballerie X; Kieny MP; Tartour E; Paul S
JAMA Netw Open; 2024 Apr; 7(4):e248051. PubMed ID: 38652471
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
7. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.
Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH
Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
[TBL] [Abstract][Full Text] [Related]
9. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes.
Pannus P; Neven KY; De Craeye S; Heyndrickx L; Vande Kerckhove S; Georges D; Michiels J; Francotte A; Van Den Bulcke M; Zrein M; Van Gucht S; Schmickler MN; Verbrugghe M; Matagne A; Thomas I; Dierick K; Weiner JA; Ackerman ME; Goriely S; Goossens ME; Ariën KK; Desombere I; Marchant A
Clin Infect Dis; 2022 Aug; 75(1):e695-e704. PubMed ID: 34864935
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection.
Schmidt KG; Harrer EG; Tascilar K; Kübel S; El Kenz B; Hartmann F; Simon D; Schett G; Nganou-Makamdop K; Harrer T
Viruses; 2022 Mar; 14(3):. PubMed ID: 35337058
[TBL] [Abstract][Full Text] [Related]
11. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
12. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
13. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
15. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
16. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Broadly Reactive Responses in Patients With MERS-CoV Infection and SARS-CoV-2 Vaccination.
Zedan HT; Smatti MK; Thomas S; Nasrallah GK; Afifi NM; Hssain AA; Abu Raddad LJ; Coyle PV; Grivel JC; Almaslamani MA; Althani AA; Yassine HM
JAMA Netw Open; 2023 Jun; 6(6):e2319222. PubMed ID: 37389876
[TBL] [Abstract][Full Text] [Related]
18. mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron.
Lee HK; Knabl L; Moliva JI; Knabl L; Werner AP; Boyoglu-Barnum S; Kapferer S; Pateter B; Walter M; Sullivan NJ; Furth PA; Hennighausen L
Cell Rep; 2022 Apr; 39(2):110680. PubMed ID: 35395191
[TBL] [Abstract][Full Text] [Related]
19. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
20. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
